Mad Hedge Biotech and Healthcare Letter
October 8, 2024
Fiat Lux
Featured Trade:
(THE LITTLE RNA THAT COULD)
(RGLS), (ALNY), (RHHBY), (NVS), (AZN), (QGEN)
Mad Hedge Biotech and Healthcare Letter
October 8, 2024
Fiat Lux
Featured Trade:
(THE LITTLE RNA THAT COULD)
(RGLS), (ALNY), (RHHBY), (NVS), (AZN), (QGEN)
Mad Hedge Biotech and Healthcare Letter
October 3, 2024
Fiat Lux
Featured Trade:
(TESTING, TESTING… CAN THIS BIOTECH SURVIVE THE POST-PANDEMIC DROP?)
(FLGT)
If you blinked, you might have missed the meteoric rise of Fulgent Genetics (FLGT) during the pandemic.
What started as a small player in genetic testing suddenly became a heavyweight in COVID-19 diagnostics, raking in nearly a billion dollars in revenue.
But with the pandemic in the rearview mirror, investors are wondering if Fulgent is just another one-hit wonder—or if it has a real shot at a biotech encore.
Fulgent started life in 2011 as a tech-savvy genetic testing outfit. They'd take your DNA, run it through their whiz-bang machines, and spit out a report for your doctor.
Not a bad gig in a market that's set to grow at 22% annually for the next decade.
But then 2020 rolled around, and boy did the plot thicken. COVID-19 hit, and Fulgent went from 59,000 billable tests in 2019 to a mind-boggling 10 million in 2021.
Talk about being in the right place at the right time.
Their COVID performance sent Fulgent's revenue into the stratosphere, rocketing from $32.5 million in 2019 to $992.6 million in 2021.
But as we all know, what goes up must come down, and by 2023, revenue had fallen back to $289.2 million as the COVID testing frenzy fizzled out.
So, where did Fulgent go from here? That’s the billion-dollar question—literally.
With COVID-19 testing revenues all but evaporated (just $841,000 in Q2 2024, or 1% of total revenue), Fulgent is back to focusing on its core genetic testing business and mapping out new territory.
Fortunately, the company didn’t just sit on its COVID cash pile. Instead, it made several strategic acquisitions to shore up its position in the broader healthcare space.
In 2021, Fulgent bought Cytometry Specialists Inc. (CSI), a move that expanded its presence in molecular diagnostics and cancer testing.
Then, in 2022, Fulgent went on a shopping spree, picking up Inform Diagnostics—a major pathology lab—and Fulgent Pharma, which marked its entry into the therapeutic development game.
These moves signal a clear intent: Fulgent wants to transition from being a niche diagnostics firm to a full-fledged healthcare solutions provider.
And here’s where it gets more interesting. Fulgent Pharma brought along a pipeline of drug candidates, including FID-007, a novel treatment for head and neck cancer that uses advanced nano-drug delivery technology.
While this segment currently contributes zero to the top line, the upside potential is massive if any of these candidates clear FDA hurdles.
Next, let’s take a look at the numbers.
Pre-COVID, Fulgent was growing at a respectable 21% clip from 2016 to 2019, but profitability was as elusive as a straight answer from the Fed. The pandemic changed all that, flooding the company with more cash than a Vegas high roller.
Still, even as COVID revenues dried up, Fulgent's core business kept growing. Their non-COVID revenues have jumped from $32.5 million pre-pandemic to $262 million in 2023.
That's an 8-fold increase, folks. Not too shabby for a Plan B.
As of Q2 2024, Fulgent's sitting on an $838 million cash pile, with zero debt. That's a lot of dry powder for a company valued at around $700 million.
Now, valuing Fulgent is trickier than nailing jello to a wall. Its specialized industry and lack of sustained profitability in its core business make traditional metrics about as useful as a screen door on a submarine.
But if we include long-term marketable securities in our net current asset value (NCAV) calculation, we get a per-share value of $25.40.
With the stock trading at $22.70, that's a price-to-NCAV ratio of 0.89x. Historically, Fulgent has traded at much higher multiples. Smells like opportunity to me.
And remember, this valuation gives zero credit to Fulgent's operating business. If they can hit their target of 40% gross margins by year-end 2024, we could be looking at a serious re-rating of this stock.
Of course, no investment is without risk, and Fulgent's got its share.
The main worry is cash burn, especially as they venture into the cash-hungry world of drug development. For 2024, they're expecting to burn $15-17 million on therapeutics development. That's manageable for now, but it's something to keep an eye on.
There's also the risk of bad acquisitions. Fulgent's been on a buying spree, and while it's paid off so far, one bad deal could spoil the broth.
Lastly, there's the Ming Hsieh factor. The CEO owns 29% of the company, giving him more control than a puppet master. His vision sounds promising, but it's speculative and may not always align with shareholder interests.
So, what’s the bottom line here?
Fulgent Genetics is like a biotech chameleon, constantly adapting to its environment. It rode the COVID wave to financial success and is now trying to parlay that into a long-term winning strategy. I suggest you buy the dip.
Mad Hedge Biotech and Healthcare Letter
October 1, 2024
Fiat Lux
Featured Trade:
(SAILING TO BIOTECH VALHALLA)
(VKTX), (NVO), (LLY), (AMGN), (PFE)
In a market full of duds and darlings, every once in a while, you stumble upon a stock that skyrockets so fast it gives you whiplash. Viking Therapeutics (VKTX) is that stock and boy, am I glad I trusted my gut on this one.
We're talking a journey from $4 to $62 in what feels like a blink of an eye - a voyage straight to biotech Valhalla, if you will. A 1,500% gain? Somebody hand me my horn of mead – and maybe a bigger treasure chest.
See what I did there? Viking stock, sailing to Valhalla – sorry, I couldn't resist. Anyway, if you missed out on this raid, don't worry. This biotech longship is still sailing strong, and it’s only getting started.
Now, I've seen my fair share of biotech booms and busts over the years, from the dizzying heights of the genome sequencing craze to the sobering lows of failed drug trials.
But this obesity drug market? It's shaping up to be the mother of all biotech booms.
At the heart of Viking's meteoric rise is a little molecule called VK-2735, a GLP-1 / GIP receptor agonist.
In layman's terms, it's a weight loss wonder drug that's got Wall Street salivating like Pavlov's dogs at dinnertime.
And why wouldn't they? We're talking about a market that could be worth north of $150 billion annually by the early 2030s.
Let's crunch some numbers, shall we? In the first half of 2024, Novo Nordisk's (NVO) dynamic duo, Ozempic and Wegovy, raked in a cool $11.7 billion.
Not to be outdone, Eli Lilly's (LLY) tag team of Mounjaro and Zepbound pulled in $6.66 billion. That's enough cash to make even a seasoned hedge fund manager's eyes water.
But here's where it gets really interesting. Viking's VK-2735, in its Phase 2 Venture study, showed weight loss results that could make even the most stubborn bathroom scale do a double-take. We're talking up to 14.7% weight loss from baseline in just 13 weeks.
Now, before you start maxing out your credit cards to buy Viking stock, let's pump the brakes a bit. This data is still in its infancy, like a toddler taking its first wobbly steps.
We're talking about a study with just 35 patients. That's barely enough people to fill a small yoga class, let alone stake billions of dollars on.
And let's not forget about safety. While VK-2735 seems to be playing nice overall, there are a few wrinkles to iron out.
The highest dose saw a 20% dropout rate, which is about as concerning as finding a shark in your swimming pool. Most patients experienced some side effects, with nausea, diarrhea, and constipation leading the pack.
Not exactly a walk in the park, but then again, no pain, no gain, right?
Looking ahead, Viking's still got its work cut out. They're aiming to kick off a Phase 3 study by Q1 2025, which means we might not see VK-2735 hit the market until Q1 2027. In biotech years, that's practically an eternity.
But here's the kicker - this delay might actually work in Viking's favor. While they're dotting their i's and crossing their t's, Novo Nordisk and Eli Lilly are out there doing the heavy lifting, expanding the market and greasing the wheels with insurers.
Still, Viking's not resting on its laurels. They're working on a monthly dosing regimen and an oral version of VK-2735.
If they pull that off, it could be a game-changer. After all, who wouldn't prefer popping a pill over jabbing themselves with a needle?
Of course, this isn't a one-horse race. The obesity drug market is starting to look like a biotech version of the Oklahoma Land Rush, with everyone from Amgen (AMGN) to Pfizer (PFE) trying to stake their claim.
But with $935 million in the bank and a net loss of only $50 million for the half-year, Viking's got the financial firepower to go the distance.
So, what's the play here? Well, given the market's current love affair with all things GLP-1, Viking's strong financial position, and the potential of both VK-2735 and their NASH candidate VK2809, I'm cautiously bullish on Viking stock.
It's a high-risk, high-reward proposition, but then again, isn't that what makes this game so damn exciting? Just don't forget to pack your Dramamine - this ride's bound to have some turbulence.
Mad Hedge Biotech and Healthcare Letter
September 26, 2024
Fiat Lux
Featured Trade:
(GOWN UP FOR SUCCESS)
(UHS)
Well, folks, it looks like we've stumbled upon a diamond in the rough in the healthcare sector. Universal Health Services (UHS) has caught my eye, and let me tell you, it's not just because I've spent more time in hospitals lately than I care to admit. (Note to self: skydiving and arthritis don't mix.)
Now, I've been around a while, and I've learned to spot a good deal when I see one. UHS is trading at a valuation that's making my wallet itch. We're talking about a forward P/E of just 13x based on analysts' 2025 EPS estimates of $17.85.
To put that in perspective, it's like finding a Rolex at a yard sale - the Medical Care Facilities industry is strutting around with a 17x forward P/E.
And here's where it gets really interesting. UHS is sporting a PEG ratio of 0.62. For those of you who dozed off during Finance 101, that's like getting a growth stock at a value price. The industry average is sitting pretty at 1.56, making UHS look like an absolute steal.
Now, let's talk about what UHS actually does. They're in the business of owning and operating acute care hospitals, outpatient facilities, and behavioral healthcare centers.
As of Q2 2024, they've got 359 inpatient facilities and 48 outpatient joints spread across 39 states, D.C., Puerto Rico, and even jolly old England.
The company operates under two main segments: Acute Care Hospital Services, which brings in about 87% of the bacon, and Behavioral Health Services, accounting for the remaining 13%.
Inpatient revenue from both segments makes up roughly 64% of total revenue, with outpatient services filling in the rest.
Now, here's where things get even more interesting. The global hospital services market is expected to expand quickly – we're talking about a 6.4% annual growth rate, potentially hitting $21 billion by 2032.
But UHS isn't just sitting pretty waiting for the market to grow. Oh no, they're expanding faster than a tech startup with too much venture capital.
They've got plans for 12 new freestanding emergency departments, a 150-bed acute care hospital under construction in Vegas (because what happens in Vegas... might need medical attention), a 136-bed hospital in D.C. set to open in spring 2025, and a 150-bed facility in Palm Beach Gardens, Florida, ready to roll in spring 2026.
And let's not forget about their Behavioral Health segment. They recently opened a 128-bed behavioral hospital in California and are cooking up a 96-bed joint venture in West Michigan.
Now, I've seen my fair share of companies promise the moon and deliver a mere pebble, but UHS seems to be putting their money where their mouth is.
Just in Q2 2024, they saw their gross margin jump from 39% to 42.6% year-over-year. Operating income margin? Up from 7.9% to 11.2%. Net income margin? A healthy increase from 4.8% to 7.4%.
And they're not just calling it a lucky quarter - they're expecting to keep this party going for the next few periods.
With all this good news, UHS has bumped up their 2024 EPS guidance by a whopping 17% to $15.80 per diluted share.
On top of all these, they've also increased their stock repurchase program by $1 billion, bringing the total authorization to $1.228 billion.
For those of you who slept through that part of business school too, that's like making your slice of the pie bigger without having to bake a new one.
Now, I'm not saying UHS is without risks. They've got a high concentration of revenue in California, Nevada, and Texas. It's like they're betting big on blackjack, roulette, and Texas Hold'em all at once. Any major changes in these states' regulations, economy, or even weather patterns could hit UHS hard.
They're also heavily reliant on Medicare and Medicaid reimbursements. So if Uncle Sam decides to tighten the purse strings, UHS could feel the pinch.
Plus, they're required to treat emergency patients regardless of their ability to pay. A sudden influx of non-paying customers could put a dent in their profits faster than you can say "insurance claim denied."
But overall, the prognosis for UHS looks good. With their margin increases, strong earnings growth, positive stock momentum, and that juicy low valuation, they're poised to be the frontrunners of the global hospital services market.
In my decades of watching the markets, I've learned that sometimes the best opportunities come wrapped in hospital gowns rather than pinstripe suits. UHS might just be one of those opportunities.
I suggest you add it to your watchlist. And if the market hiccups and gives us a dip? Well, that might just be the perfect time to scoop some up for your portfolio.
Mad Hedge Biotech and Healthcare Letter
September 24, 2024
Fiat Lux
Featured Trade:
(KNOW WHEN TO HOLD ‘EM)
(LLY), (NVO), (VKTX)
Ever stumble upon a treasure chest you almost walked past? That's how I feel about Eli Lilly (LLY) these days. When I last weighed in on LLY earlier this year, I was hesitant, pretty much like a seasoned sailor eyeing stormy seas.
The stock's valuations at the time were sky-high, especially when stacked against its arch-rival Novo Nordisk A/S (NVO). But the market, ever the trickster, loves to flip the script when you least expect it.
Since May, LLY has soared by an impressive 24.5%, leaving most of its pharmaceutical peers scrambling in its wake. Only Viking Therapeutics (VKTX) has managed to keep pace in this high-stakes race.
So, what's ignited this rocket?
For starters, Eli Lilly finally ironed out the kinks in its supply chain. By early August 2024, the shortages plaguing their weight-loss blockbuster, Mounjaro, were a thing of the past.
Those bottlenecks had put a damper on Mounjaro's performance in the first half of 2024, but now the gates have swung wide open.
But that's not all. LLY's got some serious production muscle coming online from the first half of 2025. This isn't just adding fuel to the fire — it's like pouring jet fuel on a bonfire.
That means we could see Mounjaro and Zepbound sales shooting for the moon in late 2024.
Now, here's the masterstroke. In January 2024, Eli Lilly launched LillyDirect, a direct-to-consumer platform that's nothing short of ingenious.
By slashing prices for self-pay patients on Zepbound, they're not just expanding their market reach—they're throwing a wrench into the burgeoning market for compounded GLP-1 drugs.
Let's crunch some numbers for more context.
A four-week supply of 2.5 mg Zepbound via LillyDirect costs $399 out of pocket. That's in the same ballpark as the $199 monthly fee charged by telehealth platforms like Hims & Hers Health (HIMS) for compounded GLP-1 injectables.
Contrast that with the eye-watering $1,790 monthly price tag for Novo Nordisk's Ozempic or the $1,990 for Wegovy, and it's clear why Lilly's strategy is turning heads and opening wallets.
All this momentum has Lilly's management grinning like the cat that ate the canary. They've bumped up their 2024 revenue guidance to a staggering $46 billion — a 34.8% year-over-year leap.
As for earnings, they're forecasting an adjusted EPS of $16.35, a jaw-dropping 158.7% increase from last year. Even a market veteran like me has to tip his hat.
Wall Street analysts are also joining the party, projecting Lilly's top and bottom lines to grow at a compound annual growth rate of 26.1% and 66.7%, respectively, through 2026.
Now, you might be scratching your head and thinking, "Isn't LLY overvalued at this point?"
Surprisingly, despite a forward P/E ratio of 55.39x — well above its historical averages — Lilly's forward PEG ratio sits at a comfortable 1.30x. That's lower than its 5-year mean of 2.19x and even the sector median of 2.00x.
In plain English, there's still some juice left in this orange for value investors.
But let's not get ahead of ourselves. Viking Therapeutics is hot on Lilly's heels with its VK2735 candidate, boasting impressive Phase 3 trial results.
Imagine 14.7% weight loss from baseline in just 13 weeks with their injectable version — that's actually warp speed compared to Lilly's current offerings.
And it's not just Viking sharpening their knives. The GLP-1 arena is set to become a battlefield, with up to 16 new drugs potentially launching by 2029.
So, where does that leave us? I'm cautiously upgrading Eli Lilly to a Buy, but I'm keeping my eyes wide open.
The market is frothy, perhaps a bit too exuberant for my taste. You might want to hold your horses and wait for a pullback into the $780–$845 range before jumping in.
Keep an eye on Lilly's balance sheet, too. Expansion at this scale doesn’t come cheap.
The company’s net debt has swelled to $25.53 billion, a hefty 59.6% increase from last year. Annualized interest expenses are creeping up as well, now at $734.4 million.
It’s not a five-alarm fire, but it’s smoke worth watching.
Eli Lilly has made bold moves in the GLP-1 market, positioning itself as a leader while others scramble to catch up. The question is, are you ready to take a seat at the table?
After all, in the words of the great Kenny Rogers, "You've got to know when to hold 'em, know when to fold 'em." And right now, LLY's hand is looking pretty strong.
Mad Hedge Biotech and Healthcare Letter
September 19, 2024
Fiat Lux
Featured Trade:
(THE KING’S SPEECH)
(ABT), (DXCM), (LLY), (NVO)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.